MTOR and Parkinson disease: Moreover, treatment with a compound (Genz-123346) that inhibits glycosphingolipid biosynthesis decreases mTOR activity and restores TFEB expression in GBA-PD iPSC neurons, demonstrating a possible link between mTOR-TFEB alterations and lipid accumulation [68].